



Average FY Product Sales Consensus

€m	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV*
Core Products									
Cimzia	1,799	1,868	1,933	1,961	1,867	1,593	1,345		5,463
Vimpat	1,451	1,535	953	636	546	493	441		2,076
Keppra	788	848	709	630	572	527	485		2,219
Briviact	288	351	421	488	547	595	565	625	1,735
Neupro	311	299	261	228	198	174	157		648
New products**									
Evenity		473	649	802	936	1,047	1,123	1,388	2,248
Nayzilam	26	49	75	97	116	130	136	172	419
Potential new product launches**									
Bimzelx (Bimekizumab)		43	291	625	1,016	1,422	1,816	2,872	7,724
Zilucoplan		0	8	111	269	421	575	1,076	1,927
Rozanolixizumab (Rozimab)		0	8	78	200	348	516	1,109	1,493
Dapimab		0	0	1	5	39	129		
Staccato alprazolam		0	0	4	28	79	122		
Bepranemab		0	0	19	59	148	239		

* If cell blank: not sufficient data available

**global sales, non-risk adj.

Median FY Product Sales Consensus

€m	2020a	2021e	2022e	2023e	2024e	2025e	2026e	Peak Sales	NPV*
Core Products									
Cimzia	1,799	1,855	1,940	1,978	1,863	1,538	1,313		5,126
Vimpat	1,451	1,534	952	618	538	483	417		2,192
Keppra	788	870	721	636	572	526	485		2,070
Briviact	288	349	420	490	553	590	569	616	1,677
Neupro	311	301	254	214	192	174	156		559
New products**									
Evenity		468	680	810	927	1,051	1,081	1,328	2,323
Nayzilam	26	49	74	94	113	130	136	160	430
Potential new product launches**									
Bimzelx (Bimekizumab)		36	292	627	1,021	1,378	1,766	2,632	6,539
Zilucoplan		0	0	95	259	416	552	1,063	1,915
Rozanolixizumab (Rozimab)		0	0	78	194	348	540	1,020	1,601
Dapimab		0	0	0	0	37	88		
Staccato alprazolam		0	0	0	24	66	83		
Bepranemab		0	0	0	3	75	168		

* If cell blank: not sufficient data available

**global sales, non-risk adj.

Based on the estimates of 18 brokers

Last updated: 20/09/21